Key Takeaways
- • Aptadir Therapeutics, a Milan-based biotech company, closed a €40 million ($45 million) seed funding round led by 4BIO Capital to advance its pipeline of RNA-based therapeutics for genetic conditions.
- • The company's lead candidate, CAP1-FMR1, targets Fragile X Syndrome using a proprietary technology platform based on DNMTs Interacting RNAs (DiRs) designed to reverse aberrant DNA methylation and abnormal gene silencing at the single-gene level.
- • Follow-on investors include EXTEND (CDP Venture Capital SGR's pre-seed vehicle), Angelini Ventures, Evotec SE, Indaco Venture Partners, XGEN Venture, CE-Ventures, Kerna Ventures, Italian Angels for Biotech, and Club degli Investitori, demonstrating broad institutional backing across European and Italian venture ecosystems.
- • The underlying science originates from Beth Israel Deaconess Medical Center, the Italian Research National Council, and the Cancer Science Institute of Singapore, positioning the company at the intersection of academic research and commercial therapeutics development.
Summary
Aptadir Therapeutics, a Milan-based biotechnology company, has successfully closed a €40 million ($45 million) seed financing round, marking a significant capital injection for the advancement of its RNA-based therapeutic pipeline. The round was led by 4BIO Capital, with participation from a broad consortium of institutional and strategic investors including EXTEND (the pre-seed vehicle launched by CDP Venture Capital SGR), Angelini Ventures, and Evotec SE. This investor composition reflects confidence from both European venture capital firms and established pharmaceutical stakeholders in the company's technology platform and clinical strategy.
The capital will be deployed to advance Aptadir's pipeline of disease-modifying investigational RNA therapeutics, with particular focus on its lead candidate CAP1-FMR1 for Fragile X Syndrome. The company has developed a proprietary technology platform centered on a novel class of RNAs called DNMTs Interacting RNAs (DiRs). This platform operates through a distinct mechanism: blocking aberrant DNA methylation at the single-gene level, with the goal of reversing abnormal gene silencing—a therapeutic approach addressing a significant unmet need in rare genetic disorders where epigenetic dysregulation drives pathology.
The scientific foundation for Aptadir's technology is rooted in collaborative research spanning three major institutions: Beth Israel Deaconess Medical Center, the Italian Research National Council, and the Cancer Science Institute of Singapore. This academic pedigree provides both scientific credibility and IP foundation critical for institutional investors evaluating early-stage biotech ventures. Beyond the lead investors, the round attracted participation from additional institutional backers including CDP Venture Capital, Indaco Venture Partners, XGEN Venture, CE-Ventures, Kerna Ventures, Italian Angels for Biotech, and Club degli Investitori, underscoring broad regional and sector support for the company's therapeutic approach and market opportunity in rare genetic disease treatment.
The capital will be deployed to advance Aptadir's pipeline of disease-modifying investigational RNA therapeutics, with particular focus on its lead candidate CAP1-FMR1 for Fragile X Syndrome. The company has developed a proprietary technology platform centered on a novel class of RNAs called DNMTs Interacting RNAs (DiRs). This platform operates through a distinct mechanism: blocking aberrant DNA methylation at the single-gene level, with the goal of reversing abnormal gene silencing—a therapeutic approach addressing a significant unmet need in rare genetic disorders where epigenetic dysregulation drives pathology.
The scientific foundation for Aptadir's technology is rooted in collaborative research spanning three major institutions: Beth Israel Deaconess Medical Center, the Italian Research National Council, and the Cancer Science Institute of Singapore. This academic pedigree provides both scientific credibility and IP foundation critical for institutional investors evaluating early-stage biotech ventures. Beyond the lead investors, the round attracted participation from additional institutional backers including CDP Venture Capital, Indaco Venture Partners, XGEN Venture, CE-Ventures, Kerna Ventures, Italian Angels for Biotech, and Club degli Investitori, underscoring broad regional and sector support for the company's therapeutic approach and market opportunity in rare genetic disease treatment.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.